RT Book, Section
A1 Jacobson, Caron A.
A1 Longo, Dan L.
A2 Jameson, J. Larry
A2 Fauci, Anthony S.
A2 Kasper, Dennis L.
A2 Hauser, Stephen L.
A2 Longo, Dan L.
A2 Loscalzo, Joseph
SR Print(0)
ID 1180837238
T1 Non-Hodgkin’s Lymphoma
T2 Harrison's Principles of Internal Medicine, 20e
YR 2018
FD 2018
PB McGraw-Hill Education
PP New York, NY
SN 9781259644016
LK accesspharmacy.mhmedical.com/content.aspx?aid=1180837238
RD 2024/04/23
AB Non-Hodgkin’s  lymphomas  (NHL)  are  cancers  of  mature  B,  T,  and  NK  cells.  They  were  distinguished  from  Hodgkin  lymphoma  (HL)  upon  recognition  of  the  Reed-Sternberg  (RS)  cell,  and  differ  from  HL  with  respect  to  their  biologic  and  clinical  characteristics.  Whereas  ~80–85%  of  patients  with  HL  will  be  cured  of  their  lymphoma  by  chemotherapy  with  or  without  radiotherapy,  the  prognosis  and  natural  history  of  NHL  tends  to  be  more  variable.  NHL  can  be  classified  as  either  a  mature  B-NHL,  or  a  mature  T/NK-NHL  depending  on  whether  the  cancerous  lymphocyte  is  a  B,  T,  or  NK-cell,  respectively.  Within  each  category  are  lymphomas  that  grow  quickly  and  behave  aggressively,  as  well  as  lymphomas  that  are  more  indolent,  or  slow  growing  in  nature.  For  a  list  of  the  World  Health  Organization  (WHO)  classification  of  lymphoid  neoplasms,  see  Table  104-1.